John M Vierling
Affiliation: Texas Medical Center
- Future Treatment Options in PBCJohn M Vierling
Baylor Liver Health, Baylor College of Medicine, Houston, TX 77030, USA
Semin Liver Dis 25:347-63. 2005..Induction of tolerance in susceptible people before onset of disease or of hyporesponsiveness in established disease is increasingly feasible, as is prevention of biliary fibrosis...
- Etiopathogenesis of primary sclerosing cholangitisChristine A O'Mahony
Department of Surgery, Baylor Liver Health, Baylor College of Medicine, Houston, Texas 77030, USA
Semin Liver Dis 26:3-21. 2006..Progressive periductal fibrosis, chronic inflammation, and ischemic atrophy of biliary epithelia result in ductopenia, cholestasis, and obstructive strictures, culminating in secondary biliary cirrhosis...
- Diagnosis and treatment of autoimmune hepatitisJohn M Vierling
Liver Center, Baylor College of Medicine, St Luke s Episcopal Hospital, Houston, TX 77030, USA
Curr Gastroenterol Rep 14:25-36. 2012....
- Boceprevir for chronic HCV genotype 1 infection in patients with prior treatment failure to peginterferon/ribavirin, including prior null responseJohn M Vierling
Baylor College of Medicine, Houston, TX, United States Electronic address
J Hepatol 60:748-56. 2014..We studied the efficacy of BOC/PR in patients with prior treatment failure, including those with a null response (<2-log10 decline in HCV RNA), to peginterferon/ribavirin...
- The role of biliary epithelial cells in the immunopathogenesis of non-suppurative destructive cholangitis in murine hepatic graft-versus-host diseaseJohn M Vierling
Trans Am Clin Climatol Assoc 122:326-35. 2011....
- The immunology of hepatitis BJohn M Vierling
Baylor College of Medicine, 1709 Dryden, Suite 1500, Houston, TX 77030, USA
Clin Liver Dis 11:727-59, vii-viii. 2007..Replicative intermediates can persist in the liver under immunologic control after resolution of acute or chronic hepatitis B, conferring a risk for reactivation following a course of immunosuppression or chemotherapy...
- Low rates of hepatitis B virus screening at the onset of chemotherapyJessica P Hwang
The University of Texas MD Anderson Cancer Center, Houston, TX, USA
J Oncol Pract 8:e32-9. 2012..Previous studies have shown low screening rates, but no large-scale US studies have been conducted. We sought to determine predictors of screening and positive HBV test results in patients receiving chemotherapy...
- Hepatitis B virus management to prevent reactivation after chemotherapy: a reviewJessica P Hwang
The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Support Care Cancer 20:2999-3008. 2012..Conflicting recommendations regarding HBV screening in cancer patients awaiting chemotherapy mean that some patients at risk for HBV reactivation are not being identified and treated with prophylactic antiviral therapy...
- Trends in hepatitis B virus screening at the onset of chemotherapy in a large US cancer centerJessica P Hwang
Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 1465, Houston, Texas 77030, USA
BMC Cancer 13:534. 2013..We aimed to determine contemporary screening rates at a cancer center and the possible influence on these rates of publication of national recommendations...
- An overview of emerging therapies for the treatment of chronic hepatitis CJawad A Ilyas
Liver Center, St Luke s Episcopal Hospital, Baylor College of Medicine, 1709 Dryden, Suite 1500, Houston, TX 77030, USA Department of Medicine, Baylor College of Medicine, 1709 Dryden Street, Suite 500, Houston, TX 77030, USA Department of Surgery, Baylor College of Medicine, 1709 Dryden Street, Suite 1500, Houston, TX 77030, USA
Med Clin North Am 98:17-38. 2014..Patients with CHC should continue to consider participation in clinical trials of new therapies to accelerate progress...
- Liver transplantation in autoimmune liver diseasesJawad A Ilyas
Fellow in Hepatology and Liver Transplantation, Liver Center, Baylor College of Medicine and St Luke s Episcopal Hospital, 1709 Dryden, Suite 1500, Houston, TX 77030, USA
Best Pract Res Clin Gastroenterol 25:765-82. 2011..Better understanding of the pathogenesis of recurrent autoimmune liver diseases is needed to devise effective means of prevention and treatment...
- Hepatitis C virus viral assays in the direct-acting antiviral eraJohn M Vierling
Department of Medicine, Liver Center, Baylor College of Medicine, Houston, TX 77030, USA
Clin Liver Dis 17:27-45. 2013..Only quantitative HCV RNA assays with a limit of detection of 10 to 15 IU/mL are appropriate for managing patients on DAA therapy...
- Acute liver failureN Thao T Nguyen
Michael E DeBakey Department of Surgery, Baylor College of Medicine, Houston, Texas 77030, USA
Curr Opin Organ Transplant 16:289-96. 2011..The purpose of this review is to summarize the advances in clinical research in ALF during 2009-2010 that are pertinent to hepatologists and transplant surgeons caring for these critically ill patients...
- Justice, administrative law, and the transplant clinician: the ethical and legislative basis of a national policy on donor liver allocationNeal R Barshes
Michael E DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX, USA
J Contemp Health Law Policy 23:200-30. 2007
- Hepatitis B and hepatitis C prevalence and treatment referral among Asian Americans undergoing community-based hepatitis screeningJessica P Hwang
Department of General Internal Medicine at University of Texas M D Anderson Cancer Center, Houston, USA
Am J Public Health 100:S118-24. 2010..We sought to identify cross-sectional hepatitis B virus (HBV) and HCV prevalence among Asian Americans at a community health fair and to assess referral rates...
- Interaction of CD44 and hyaluronic acid enhances biliary epithelial proliferation in cholestatic liversYao He
Comprehensive Transplant Center, Department of Surgery, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
Am J Physiol Gastrointest Liver Physiol 295:G305-12. 2008..CD44-hyaluronan interaction, by enhancing biliary proliferation, may play a pathogenic role in the development of cholestatic liver diseases...
- The clinical and immunologic impact of using interferon and ribavirin in the immunosuppressed hostMarius Braun
Center for Liver Diseases and Transplantation and Burns and Allen Research Institute, Cedars Sinai Medical Center, and the David Geffen School of Medicine at UCLA, Los Angeles, CA 90048, USA
Liver Transpl 9:S79-89. 2003..8. After new, less toxic, and more potent antiviral agents become available, they should be tested immediately in patients with hepatitis C post-liver transplantation...
- Primary biliary cirrhosis and autoimmune cholangiopathyJohn M Vierling
Center for Liver Diseases and Transplantation, Los Angeles, CA 90048, USA
Clin Liver Dis 8:177-94. 2004....
- Limited role for CXC chemokines in the pathogenesis of alpha-naphthylisothiocyanate-induced liver injuryJunquan Xu
Liver Center and Department of Medicine, University of California, San Francisco 94110, USA
Am J Physiol Gastrointest Liver Physiol 287:G734-41. 2004....
- Early hepatic nodular hyperplasia and submicroscopic fibrosis associated with 6-thioguanine therapy in inflammatory bowel diseaseStephen A Geller
Department of Pathology and Laboratory Medicine, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
Am J Surg Pathol 28:1204-11. 2004..6-TG-related hepatotoxicity, including liver biochemistry value elevations, sinusoidal collagen deposition on electron microscopy, and veno-occlusive disease, have been described related to its use as therapy for neoplastic disease...
- Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patientsM Eric Gershwin
Division of Rheumatology, Allergy and Clinical Immunology, University of California at Davis School of Medicine, Davis, CA 95616, USA
Hepatology 42:1194-202. 2005..Exogenous estrogens may also contribute to explain the female predominance of the disease...
- T cell immunity and graft-versus-host disease (GVHD)Yasunori Ichiki
Division of Rheumatology, Allergy and Clinical Immunology, University of California at Davis School of Medicine, TB192, One Shields Avenue, Davis, CA 95616, USA
Autoimmun Rev 5:1-9. 2006..Chronic GVHD involves a wider range of organs and clinical manifestations include scleroderma, liver failure, immune complex disease, glomerulonephritis, and autoantibody formation...
- Management of patients with cirrhosis in Southern California: results of a practitioner surveySammy Saab
Department of Medicine, David Geffen School of Medicine at UCLA, University of California Los Angeles, Los Angeles, CA, USA
J Clin Gastroenterol 40:156-61. 2006..A paucity of data exists on how patients with cirrhosis are managed. Our aims were to determine how cirrhosis is managed and whether current management practices follow established recommendations...
- Quality of life and everyday activities in patients with primary biliary cirrhosisCarlo Selmi
Division of Rheumatology, Allergy, and Clinical Immunology, University of California, Davis, CA 95616, USA
Hepatology 46:1836-43. 2007..Nevertheless, patients with PBC suffer significantly more than controls from a variety of symptoms that are beyond the immediate impact of liver failure and affect their lifestyle, personal relationships, and work activities...
- Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapyRobert J Fontana
Department of Medicine, University of Michigan, Ann Arbor, Michigan, USA
Gastroenterology 123:719-27. 2002....